Anebulo Pharmaceuticals Reports Q2 Results Amidst Nasdaq Delisting Timeline

summarizeSummary

Anebulo Pharmaceuticals reported Q2 FY2026 financial results, including a $2.0 million net loss and $9.0 million cash, while providing a detailed timeline for its voluntary Nasdaq delisting and SEC deregistration.

check_boxKey Events

• Q2 FY2026 Financial Results

  Reported a net loss of $2.0 million, or $(0.05) per share, for the quarter ended December 31, 2025, compared to a $2.5 million loss in the prior year.

• Cash Position

  Held $9.0 million in cash and cash equivalents as of December 31, 2025, with access to an additional $3.0 million loan.

• Nasdaq Delisting Timeline Confirmed

  Detailed the timeline for voluntary delisting from Nasdaq, with Form 25 filing expected on February 17, 2026, and delisting effective February 27, 2026.

• Deregistration with SEC

  Intends to file Form 15 on or about February 27, 2026, to suspend SEC reporting obligations, citing cost savings as the primary reason.

auto_awesomeAnalysis

This 8-K provides the financial context for Anebulo Pharmaceuticals' recent decision to delist from Nasdaq, reporting a net loss of $2.0 million for the quarter and $9.0 million in cash. The filing also details the timeline for the voluntary delisting and deregistration, with Form 25 expected on February 17, 2026, and delisting effective February 27, 2026. This confirms the company's financial challenges and its strategic shift away from public reporting to reduce costs and focus on its lead product candidate. Investors should note the limited cash runway given the burn rate and the impending cessation of Nasdaq trading.